Catabasis Pharmaceuticals
| Region | Nordamerika |
| ISIN | US14875P2065 |
| Sektor | Biotechnologie |
| Website | https://www.catabasis.com/ |
At Catabasis Pharmaceuticals, our mission is to bring hope and life-changing therapies to patients and their families. Our lead program is edasalonexent, an NF-kB inhibitor in development for the treatment of Duchenne muscular dystrophy. Our global Phase 3 PolarisDMD trial is currently enrolling boys affected by Duchenne. For more information on edasalonexent and our Phase 3 PolarisDMD trial, please visit www.catabasis.com or www.twitter.com/catabasispharma.
| Titel | Autor | Datum |
|---|---|---|
|
Der heißeste Buyout-Kandidat des Jahres!
2 Kommentare |
Hai | vor ungefähr 9 Monaten |
| Titel | Datum |
|---|---|
| Catabasis Pharmaceuticals' (CATB) CEO Jill Milne on Q3 2019 Results - Earnings Call Transcript | vor 6 Tagen |
| CATABASIS PHARMACEUTICALS INC - 10-Q, Quaterly Report | vor 7 Tagen |
| Aktienexperte ist von der Catabasis Aktie begeistert wie noch nie | vor 25 Tagen |
| CATABASIS PHARMACEUTICALS INC - 8-K, Current Report | vor 28 Tagen |
| 5 Top Gainers In Healthcare Sector (OCGN, CATB, SOLY) | vor ungefähr einem Monat |
| Diese Aktien könnten Dich auch interessieren | |
|---|---|
| Cannabis Wheaton Income (2 Artikel) | |
| BYD Company (1 Artikel) | |
| CBLT (1 Artikel) | |
| Celgene (1 Artikel) | |
| Alle anzeigen | |